

Postmarketing Drug Safety Compliance: 2019 Inspection Findings

April 29, 2020 (Live Webinar)

Center for Drug Evaluation and Research – Small Business and Industry Assistance

Namita Kothary, PharmD, RAC (US) Pharmacovigilance Compliance Team, Postmarketing Safety Branch Division of Enforcement and Postmarketing Safety Office of Compliance, Office of Scientific Investigations Center for Drug Evaluation and Research, US Food and Drug Administration





 Identify the role of FDA's Postmarketing Adverse Drug Experience (PADE) Compliance Program

2. Describe recent PADE inspection findings and trends





- 1. Overview of FDA's PADE Compliance Program
- 2. Fiscal Year 2019* Inspection Site Selection
- 3. Fiscal Year 2019* Inspection Findings and Trends
- 4. PADE Compliance in a Pandemic Situation


*Fiscal Year 2019 (FY2019): 01-Oct-2018 to 30-Sep-2019

Compliance Mission



Shield patients from poor quality, unsafe, and ineffective drugs through proactive compliance strategies and risk-based enforcement actions





www.fda.gov Examples of PADE laws and regulations provided at the end of this presentation 5

PADE Inspection Process

CDER performs risk-based selection of inspection sites

CDER communicates inspection outcome to inspected entity

CDER determines final classification based on EIR, evidence, and firm response CDER issues inspection to FDA Office of Regulatory Affairs - Bioresearch Monitoring (BIMO) program

BIMO investigator conducts inspection

BIMO investigator provides establishment inspection report (EIR) and initial classification

www.fda.gov

FDA

Inspection Classifications



No Action Indicated (NAI)

Objectionable conditions or practices were not found

Voluntary Action Indicated (VAI)

Objectionable conditions or practices found, but do not rise to the level of regulatory action

Official Action Indicated (OAI)

Regulatory and/or administrative actions recommended, such as: Untitled letter, Warning letter, Regulatory meeting



PADE Compliance Program

Objectives


- ✓ Assure safe and effective human drugs are available
- Verify accuracy, reliability, and timeliness of postmarketing data submitted to FDA
- ✓ Support FDA reviewers by ensuring that they receive drug safety data required for the continual evaluation of product safety
- ✓ Monitor industry compliance with PADE reporting requirements

What is an adverse experience?




Any adverse event associated with the use of a drug or biological product in humans, whether or not considered product-related, including:

- Use in professional practice
- Overdose (intentional and accidental)
- Abuse
- Withdrawal
- Failure of expected pharmacological action (lack of effect)





Role of PADE Compliance In Product Lifecycle



Postmarketing safety data from real world experience is critical to FDA's safety surveillance program

Examples of safety data limitations

Limited / narrow patient population Rare adverse events are challenging to identify Surrogate endpoints may not predict clinical outcomes Short studies (long term effects unknown or not well www.fda.gov characterized)

PADE Compliance Program

Monitor industry compliance with laws and regulations

Ensure accurate, reliable, timely safety data is submitted to FDA and available to reviewers who evaluate product safety

Who do we inspect for PADE Compliance?



Application holders	Applicants with approved drugs and therapeutic biologics (prescription and non-prescription)	 New Drug Application (NDA) Abbreviated New Drug Application (ANDA) Biologics License Application (BLA)
Non- Applicants	Manufacturers, packers, distributors, retailers, and certain others named on product labels (responsibilities vary based on product type)	 Approved prescription and non-prescription drugs and therapeutic biologics (NDA, ANDA, BLA) Unapproved prescription drugs Unapproved non-prescription drugs
Third parties	Contractors, vendors, and other third parties	 Pharmacovigilance activities conducted on behalf of application holders or non-applicants
www.fda.gov		11

Risk-based Site Selection





Firm information

- Corporate changes
- Portfolio (type and number of products)
- Complaints
- Internal FDA information
- Information from other health authorities




Product Portfolio

- New molecular entities
- High-risk
- Patient exposure
- Recalls
- Submissions to FDA
 - Individual Case Safety Reports (ICSRs)
 - Annual reports
 - Periodic reports

Inspection history

- Compliance and inspection history
 - Never inspected for PADE compliance
 - Inspection findings from other program areas
- Firm's written responses to previous PADE inspections

FY2019 Sites Selected*




www.fda.gov

* Inspected entities may have more than one risk factor

FD/


FY2019 Inspection Classifications*



- NAI
- NAI with discussion items
- VAI (1 observation)
- VAI (2 observations)
- VAI (3+ observations)

www.fda.gov

FDA



Late or unreported aggregate safety reports

Late or unreported expedited ICSRs

Inadequate written procedures

Incomplete submissions

Late or unreported non-expedited ICSRs


*Based on inspection end date www.fda.gov

FDA

PADE Quality Process



Applicants and non-applicants listed on the label are responsible for ensuring compliance with PADE laws and regulations, including activities conducted on their behalf by business partners and third-parties



PADE Compliance: Pandemic Situation



FDA Guidance: "Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic"

Discusses FDA's intended approach to enforcement of PADE reporting requirements during a pandemic, considering potential:

- Impacts to the ability to function normally and comply with regulatory requirements
- Reductions in workforce
- Increases in adverse events reported for products used to manage the pandemic

Guidance available at: <u>https://www.fda.gov/regulatory-information/search-fda-guidance-</u> <u>documents/postmarketing-adverse-event-reporting-medical-products-and-dietary-supplements-during-pandemic</u>

PADE Compliance: Pandemic Situation



BeforeDuringPlan and prepare!FDA expects firms to maintain compliance for products
or issues of special concern, as communicated by FDADevelop a
Continuity of
Operations Plan
(COOP) for all
stages of
pandemicMaintain compliance to the maximum extent possible
If ability to comply is impacted (e.g. high absenteeism):
• Implement COOP

- Document pandemic dates and factors impacting compliance
- Notify FDA
- Prioritize report submissions
- Store certain reports for future submission
- Maintain records of what was stored and when processes were restored

After sume timely

Resume timely reporting of postmarketing safety information

Prioritize and submit stored reports within 6 months of restoring adverse event reporting process to prepandemic state

For More Information...



FDA Website: "Postmarketing Adverse Event Reporting Compliance Program"

Available at:

<u>https://www.fda.gov/drugs/surveillance/postmarketi</u> <u>ng-adverse-event-reporting-compliance-program</u>

Contact the Pharmacovigilance Compliance Team at <u>CDER-OSI-ADE@fda.hhs.gov</u>



PADE Statutory Provisions / Regulations: Prescription Drug Products for Human Use



FDCA, Subchapter V, Part A, Section 505 (21 USC §355)	New drugs
21 CFR 310.305	New drugs: Records and reports concerning ADEs on marketed prescription drugs for human use without approved new drug applications
21 CFR 314.80	New drug applications: Postmarketing reporting of ADEs
21 CFR 314.81(b)(2)	New drug applications: Annual reports
21 CFR 314.90	New drug applications: Waivers
21 CFR 314.98	Abbreviated applications: Postmarketing reports
21 CFR 314.540	Accelerated approval of new drugs for serious of life- threatening illnesses: Postmarketing safety reporting
21 CFR 314.630	Approval of new drugs when human efficacy studies are not ethical or feasible: Postmarketing safety reporting
21 CFR Part 4, Subpart B	Postmarketing safety reporting for combination products

PADE Statutory Provisions / Regulations: Licensed Biological Products for Human Use

	_		Δ	
E.))	Δ	
- 1	-	4		-

PHS Act, Subchapter II, Part F, Subpart 1 (42 USC §262)	Regulation of biological products
21 CFR 600.80	Biological products: Postmarketing reporting of adverse experiences
21 CFR 601.28	Biologics licensing: Annual reports of postmarketing pediatric studies
21 CFR 601.44	Accelerated approval of biological products for serious of life-threatening illnesses: Postmarketing safety reporting
21 CFR 601.70	Postmarketing studies: Annual progress reports of postmarketing studies
21 CFR 601.93	Approval of biological products when human efficacy studies are not ethical or feasible: Postmarketing safety reporting
21 CFR Part 4, Subpart B	Postmarketing safety reporting for combination products

PADE Statutory Provisions / Regulations: Unapproved, Non-prescription Products (e.g. OTC monograph)

FDCA, Subchapter VII, Part H, Section 760 (21 USC §379aa)	Serious adverse event reporting for nonprescription drugs
21 CFR 329.100	Postmarketing reporting of ADEs under section 760 of the FDCA
21 CFR Part 4, Subpart B	Postmarketing safety reporting for combination products

www.fda.gov

D/